NovaBay Pharmaceuticals Names Jack McGovern Interim CEO

By

EMERYVILLE, Calif.—NovaBay Pharmaceuticals announced that Jack McGovern has been named interim chief executive officer, expanding his responsibilities as chief financial officer to include overseeing daily operations. Mark M. Sieczkarek, the company’s previous CEO, remains NovaBay’s chairman and will focus on strategic growth opportunities that complement its continued organic growth, the company said in a statement. “We have developed a strong organizational infrastructure and implemented the key metrics that are critical to driving business success,” said McGovern.

“Of utmost importance is the tremendous opportunity in promoting Avenova as a proven product that addresses the large, underserved conditions of blepharitis and bacterial dry eye, which represents about 85 percent of the dry eye market,” McGovern said.

McGovern joined NovaBay as chief financial officer in July 2017 with more than 30 years of experience in finance and operations. Previously, he was chief operating Officer and CFO of Attainia, Inc., a SaaS-based provider of planning solutions for the health care industry sold to a private equity firm, and managing partner at Northshore Management Partners, a consultancy with an emphasis on financial capitalization, structuring and developing operational scale. Earlier, he was COO/CFO at Integrated Biosystems, a venture-stage company in France; executive vice president at Strategic Capital, a boutique investment bank with a focus on M&A and COO/CFO of Oliver-Allen Corp., a computer leasing company. He began his career with KPMG.